WallStreetZenWallStreetZen

NASDAQ: HUMA
Humacyte Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for HUMA

Based on 2 analysts offering 12 month price targets for Humacyte Inc.
Min Forecast
$10.00+186.53%
Avg Forecast
$13.50+286.82%
Max Forecast
$17.00+387.11%

Should I buy or sell HUMA stock?

Based on 2 analysts offering ratings for Humacyte Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their HUMA stock forecasts and price targets.

HUMA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
BTIG
Top 3%
98
Strong BuyMaintains$10.00+186.53%2022-07-18
Cowen & Co.
Bottom 39%
39
BuyInitiates Coverage On$17.00+387.11%2021-10-29

1 of 1

Forecast return on equity

Is HUMA forecast to generate an efficient return?
Company
-82.54%
Industry
18.78%
Market
118.57%
HUMA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HUMA forecast to generate an efficient return on assets?
Company
-47.66%
Industry
14.1%
HUMA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HUMA earnings per share forecast

What is HUMA's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$0.84-133.87%
Avg 2 year Forecast
-$0.91-136.69%
Avg 3 year Forecast
-$0.94-137.9%

HUMA revenue forecast

What is HUMA's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$2.1M+6.66%
Avg 2 year Forecast
$7.7M+295.24%
Avg 3 year Forecast
$34.6M+1,672.03%
HUMA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

HUMA revenue growth forecast

How is HUMA forecast to perform vs Biotechnology companies and vs the US market?
Company
151.49%
Industry
23.75%
Market
8.46%
HUMA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HUMA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HUMA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
HUMA$3.49$13.50+286.82%Strong Buy
AVTE$14.77N/AN/AHold
CELU$2.51$10.00+298.41%Buy
ARCT$13.62$46.00+237.74%Buy
MESO$2.80$4.75+69.64%Hold

Humacyte Stock Forecast FAQ

Is Humacyte Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: HUMA) stock is to Strong Buy HUMA stock.

Out of 2 analysts, 1 (50%) are recommending HUMA as a Strong Buy, 1 (50%) are recommending HUMA as a Buy, 0 (0%) are recommending HUMA as a Hold, 0 (0%) are recommending HUMA as a Sell, and 0 (0%) are recommending HUMA as a Strong Sell.

If you're new to stock investing, here's how to buy Humacyte stock.

What is HUMA's earnings growth forecast for 2022-2024?

(NASDAQ: HUMA) Humacyte's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.67%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.42%.

Humacyte's earnings in 2022 is $28,058,000.On average, 3 Wall Street analysts forecast HUMA's earnings for 2022 to be -$86,525,715, with the lowest HUMA earnings forecast at -$89,615,919, and the highest HUMA earnings forecast at -$81,375,374. On average, 3 Wall Street analysts forecast HUMA's earnings for 2023 to be -$93,736,191, with the lowest HUMA earnings forecast at -$103,006,803, and the highest HUMA earnings forecast at -$85,495,646.

In 2024, HUMA is forecast to generate -$96,826,395 in earnings, with the lowest earnings forecast at -$113,307,483 and the highest earnings forecast at -$79,315,238.

What is HUMA's revenue growth forecast for 2022-2024?

(NASDAQ: HUMA) Humacyte's forecast annual revenue growth rate of 151.49% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 23.75%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.46%.

Humacyte's revenue in 2022 is $1,952,000.On average, 2 Wall Street analysts forecast HUMA's revenue for 2022 to be $214,460,164, with the lowest HUMA revenue forecast at $188,502,449, and the highest HUMA revenue forecast at $240,417,878. On average, 2 Wall Street analysts forecast HUMA's revenue for 2023 to be $794,697,485, with the lowest HUMA revenue forecast at $265,757,552, and the highest HUMA revenue forecast at $1,323,637,419.

In 2024, HUMA is forecast to generate $3,563,005,316 in revenue, with the lowest revenue forecast at $1,939,618,100 and the highest revenue forecast at $5,186,392,531.

What is HUMA's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: HUMA) forecast ROA is -47.66%, which is lower than the forecast US Biotechnology industry average of 14.1%.

What is HUMA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year HUMA price target, the average HUMA price target is $13.50, with the highest HUMA stock price forecast at $17.00 and the lowest HUMA stock price forecast at $10.00.

On average, Wall Street analysts predict that Humacyte's share price could reach $13.50 by Jul 18, 2023. The average Humacyte stock price prediction forecasts a potential upside of 286.82% from the current HUMA share price of $3.49.

What is HUMA's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: HUMA) Humacyte's current Earnings Per Share (EPS) is $2.48. On average, analysts forecast that HUMA's EPS will be -$0.84 for 2022, with the lowest EPS forecast at -$0.87, and the highest EPS forecast at -$0.79. On average, analysts forecast that HUMA's EPS will be -$0.91 for 2023, with the lowest EPS forecast at -$1.00, and the highest EPS forecast at -$0.83. In 2024, HUMA's EPS is forecast to hit -$0.94 (min: -$1.10, max: -$0.77).

What is HUMA's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: HUMA) forecast ROE is -82.54%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.